@article{39513a2018fb490d938d25033f71514f,
title = "Acceptance of high platelet reactivity as a risk factor: Now, what do we do about it?",
keywords = "clopidogrel, high platelet reactivity, loss-offunction allele",
author = "Gurbel, {Paul A.} and Tantry, {Udaya S.}",
note = "Funding Information: This work was supported by grants from the Sinai Hospital of Baltimore. Dr. Gurbel has received research grants, honoraria, and consultancy fees from Schering Plough , Haemoscope , AstraZeneca , Medtronic , Lilly/Daiichi Sankyo , Sanofi-Aventis , Boston-Scientific , Bayer Healthcare , Portola Pharmaceuticals , and Pozen . Dr. Tantry reports that he has no relationships to disclose. ",
year = "2010",
month = oct,
doi = "10.1016/j.jcin.2010.08.011",
language = "English (US)",
volume = "3",
pages = "1008--1010",
journal = "JACC: Cardiovascular Interventions",
issn = "1936-8798",
publisher = "Elsevier Inc.",
number = "10",
}